Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SABS · NASDAQ · Biological Products, (No Diagnostic Substances)
Sab Biotherapeutics (SABS) · oqro.io/stocks/SABS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$2.81−0.10 (−3.44%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Sab Biotherapeutics was filed in the last 90 days. The latest on record was on Dec 7, 2023.
Since 2021, Sab Biotherapeutics insiders reported 12 open-market purchases and 1 sale on Forms 4 and 5, with purchases in 3 different years, most recently 2023.
No open-market sale by an insider of Sab Biotherapeutics (SABS) was filed with the SEC in the last 90 days.
No trade in Sab Biotherapeutics (SABS) was disclosed by a member of Congress in the last 12 months.
Sab Biotherapeutics's next results are expected on Mar 8, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−26.1% (−$0.99) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $3.80 on Nov 20, 2025 to $2.81 on Nov 20, 2026 (−26.1%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Miami Beach, Fl.
Last 12 months
−26.1%
Market value
$253M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 5.03M shares sold short (5.6% of shares outstanding), +4.7% vs the previous count, 8.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$0
−100.0% vs the year before
Net income, fiscal 2025
$13.3M
As reported in the annual filing
Shares outstanding
90.1M
As of Nov 2, 2026
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed May 29, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
—
Free cash flow, last 12 months
−$14.4M
This quarter −$14.4M
Net debt
—
Debt —, cash $14.4M, at Sep 30, 2026
Net income, last 12 months
−$80.5M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Mar 29, 2024.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
Company Overview We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
And 13 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 9, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Latest annual report filed Mar 9, 2026, compared with the one filed Mar 31, 2025. Read the filing
We are not currently a party to any material litigation, nor are we aware of any pending or threatened litigation against us that we believe would materially affect our business, operating results, financial condition, or cash flows. Participants in our industry face frequent claims and litigation, including securities litigation, claims regarding patent and other intellectual property rights, and other liability claims. As a result, we may be involved in various legal proceedings from time to time in the future.
Source: SEC EDGAR, Form 10-K filed Mar 9, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Vivo Opportunity Fund Holdings, L.P.
13G · passive · Amended · 22.3M shares · filed Nov 16, 2026
BALYASNY ASSET MANAGEMENT L.P.
13G · passive · Amended · 7.23M shares · filed Nov 16, 2026
Woodline Partners LP
13G · passive · Amended · 5.46M shares · filed Nov 16, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in type 1 diabetes. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Against the S&P 500 over the year
Since Nov 18, 2025, SABS is down 28.1% and the index fund is up 4.5%: 33 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SABS moves
Beta 1.1 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Off-exchange trading: 46.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (16.5% on ATS, 29.8% with other brokers), close to its 26-week average of 45.7%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (12.6%), BIDS ATS (12.2%), LEVEL ATS (10.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Insiders of Sab Biotherapeutics reported 12 open-market purchases and 1 sale since 2021; purchases in 3 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $16K3×3 trades | — |
| 2022 | $18K2×2 trades | — |
| 2021 | $12.7M7×7 trades | $2.2K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
Mar 29, 2024
More than 30 days ago
Next results, expected
Mar 8, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Sab Biotherapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Sab Biotherapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Things to keep in mind
On the public record for Sab Biotherapeutics over the 12 months to Nov 21, 2026: 1 clinical trial.